{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-296201","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2026-07-06T20:15:17+00:00","discovered_at":"2026-07-06T20:16:00.575371+00:00","generated_at":"2026-07-06T20:16:08.148985+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RxSight and Alcon enter collaboration to develop adjustable PCIOLs; $60M upfront, up to $140M milestones","bullets":["RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.","Alcon to pay 30% royalties on net sales of collaboration products; RxSight to develop and manufacture, Alcon to commercialize globally.","Collaboration combines RxSight's light-adjustable technology with Alcon's presbyopia-correcting IOL optics for post-operative fine-tuning.","Agreement includes non-exclusive licenses; RxSight retains U.S. regulatory approvals and will supply LDD devices.","Deal could accelerate adoption of adjustable IOLs; Alcon is global eye care leader (SIX/NYSE: ALC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-296201","json":"https://secwatch.observer/filing/0001193125-26-296201.json","markdown":"https://secwatch.observer/filing/0001193125-26-296201.md","text":"https://secwatch.observer/filing/0001193125-26-296201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/0001193125-26-296201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/rxst-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T20:16:08.148985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}